Ascentage Pharma Group International (NASDAQ:AAPG) Reaches New 1-Year Low – Should You Sell?

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) reached a new 52-week low during mid-day trading on Thursday. The company traded as low as $14.55 and last traded at $14.6290, with a volume of 9357 shares traded. The stock had previously closed at $14.94.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on AAPG. BTIG Research restated a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a research note on Friday, August 21st. Raymond James Financial reiterated a “buy” rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. Finally, B. Riley Financial started coverage on Ascentage Pharma Group International in a research note on Wednesday, June 10th. They issued a “buy” rating and a $45.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $46.43.

Ascentage Pharma Group International Stock Performance

The company’s fifty day simple moving average is $16.83 and its two-hundred day simple moving average is $19.41. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.18 and a current ratio of 1.22.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The firm had revenue of $22.24 million for the quarter. On average, equities research analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 earnings per share for the current year.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that target mechanisms involved in programmed cell death. The company’s research is primarily directed toward cancer and other serious diseases in which regulating apoptosis may offer therapeutic benefits.

Its pipeline includes small-molecule drug candidates designed to inhibit proteins that help cancer cells survive. Key programs have included lisaftoclax (APG-2575), a BCL-2 inhibitor being investigated for hematologic malignancies, and APG-115, an MDM2-p53 inhibitor under evaluation in oncology indications.